A meaningful subset of treatment-resistant depression appears to be driven substantially by inflammation, and this subset responds differently to standard versus anti-inflammatory treatment. The clinical signal is elevated peripheral inflammatory markers — most practically, hs-CRP — combined with the clinical phenotype of sickness behavior (fatigue, anhedonia, psychomotor slowing, sleep disturbance, cognitive slowing) that overlaps but is distinguishable from melancholic and atypical depression patterns. The longevity-psychiatry frame engages this subtype directly: measuring inflammation in TRD, recognizing the phenotype, and adjusting treatment to address the inflammatory contribution.
The mechanism is now well-characterized. Peripheral inflammation (elevated IL-6, TNF-alpha, CRP, others) is associated with depression in epidemiologic studies and produces depressive symptoms when induced experimentally (interferon-alpha treatment, vaccination challenges, endotoxin administration). The proximate brain mechanisms include kynurenine pathway activation (shifting tryptophan metabolism away from serotonin synthesis toward neurotoxic kynurenine metabolites), microglial activation, blood-brain barrier permeability changes, and direct cytokine effects on neurotransmitter systems. The picture is mechanistically robust: inflammation can produce depression, and chronic low-grade inflammation can produce chronic low-grade depression that does not respond well to serotonin-targeted treatment.
hs-CRP is the field-deployable marker. Values above 3 mg/L identify the inflamed subtype with reasonable specificity in TRD populations; values above 5 mg/L are highly suggestive. The interpretation requires excluding acute illness and chronic infection. Once identified, the clinical implications change: standard serotonergic antidepressants frequently fail in high-inflammation patients, while anti-inflammatory approaches (high-EPA omega-3, lifestyle interventions targeting inflammation, anti-inflammatory augmentation in selected cases) frequently produce response in the same patients. The measurement is cheap, the interpretation is straightforward, and the clinical action is defined.
Omega-3 with high EPA is the first-line anti-inflammatory augmentation. Total omega-3 dose of 1–2 grams daily with EPA component above 60% (e.g., EPA 1000 mg, DHA 500 mg) has the strongest evidence in inflammation-elevated TRD. The mechanism is anti-inflammatory (EPA-derived eicosanoids and specialized pro-resolving mediators), neuroplasticity-supporting, and membrane-stabilizing. The intervention is low-cost, well-tolerated, and supported by meta-analyses in depression generally and inflamed TRD specifically. Dose, form (triglyceride versus ethyl ester), and EPA:DHA ratio matter; the prescription should be specific.
NSAID strategies in TRD remain a research-edge intervention with selected use. Celecoxib augmentation has produced positive results in several small trials in inflammation-elevated TRD; the mechanism is COX-2 inhibition with downstream effects on neuroinflammation. The use is off-label, the long-term GI and cardiovascular risks of chronic NSAID exposure are real, and the practice should be limited to patients with clear inflammation signal, adequate trial of safer interventions, and informed conversation about the trade-offs. Minocycline (a tetracycline with anti-neuroinflammatory effects) has produced positive results in some research populations but is not yet established for routine use. The anti-inflammatory pharmacology in TRD is an emerging area; the practice should follow the evidence carefully.
Lifestyle interventions are the under-appreciated anti-inflammatory strategy. Exercise is a powerful inflammation modulator (Stage 9); sleep is a critical inflammation modulator (Stage 4); Mediterranean-pattern diet reduces inflammatory markers; smoking cessation, alcohol reduction, weight management, and stress reduction all contribute. The patient with inflamed TRD who is sedentary, sleep-disrupted, on a pro-inflammatory diet, and chronically stressed is producing the inflammatory milieu that perpetuates the depression. The clinical move is to address the lifestyle drivers of inflammation as part of TRD treatment, not as separate "wellness advice." The discipline is to measure inflammation in TRD, recognize the inflamed subtype, and adjust treatment to address the inflammation as well as the depression — the response rates in well-selected patients are substantially higher than standard treatment alone.